
From: Michael Perfetto <MPerfetto@actavis.com>
To: Sales reps and contract team@ALPHARMA
CC: Terrence Fullem; Doug Boothe; Nekela Bornell; Jinping McCormick; David Myers; Tinna Traustadottir
Sent: 9/10/2007 2:24:36 AM
Subject: Sizzle slide
Attachments: Sizzle Slide September 2007.ppt

New and improved Sizzle slide !

<<Sizzle Slide September 2007.ppt>>

Michael Perfetto
Vice President, Sales
Actavis US
Cell 908 - 868 -9778
Office 607-724-2930
Fax 607-724-0322

PLAINTIFF
TRIAL EXHIBIT
P-04421_00001

Confidential

Acquired_Actavis_00094821

P-04421 _ 00001

File Provided Natively

Global

- Actavis has acquired and successfully integrated 25 companies globally since 1999; now doing business in close to 40 countries.
- Most recent acquisitions are two sites in India (Finished Dose and API development) and Abrika (Controlled Release Development).
- 20 manufacturing sites in 11 countries with a capacity of 24 billion tabs/caps.
- Global pipeline of 377 development projects; 70 pending ANDA's with \$20+ billion in brand sales.
- Actavis becomes a private company - same management, but with enhanced flexibility for action.

U.S. Market

- 14 U.S. product launches in 2006; 23-27 projected in 2007.
- Recent major launches include: Fentanyl Patch, Finasteride, Glipizide ER, Rantidine Liquid, Propranolol ER, Nifedipine XR, Griseofulvin...and more.
- Additional First to File on Ambien CR 6.25 mg, Ritalin LA and Clobetasol Lotion.
- Currently engaged in over 25 active projects involving purchase acquisition of products and companies.
- “Actavis almost fits the model of our ‘perfect’ company. It has a good regional spread, strong R&D capabilities and the chance to optimize production”. - Merrill Lynch

